NCT06997068 2026-04-03
Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population
Mayo Clinic
Phase 2 Recruiting
Clinical Trials
23 trialsNCT04162873 2025-02-12
Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer
University of Utah
Phase 2 Terminated
NCT04176419 2024-11-12
Perioperative Analgesia on Postoperative Opioid Usage and Pain Control in H&N Cancer Surgery
Case Comprehensive Cancer Center
Phase 3 Terminated
NCT02748707 2022-04-28
ERLO-XIB
Tata Memorial Hospital
Phase 2 Unknown
NCT00052611 2018-03-29
Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00400374 2018-03-15
Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2
Emory University
Phase 1 Completed
NCT00970502 2017-04-10
Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT00953849 2017-03-07
Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity
VA Office of Research and Development
Phase 1/2 Completed
NCT02739204 2016-04-15
Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma
China Medical University Hospital
Phase 2 Unknown
NCT02537925 2015-09-02
The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma
Nanning Second People's Hospital
Phase 3 Unknown
NCT00934739 2015-02-25
A Study of High-Risk Oral Cavity Cancer
National Health Research Institutes, Taiwan
Phase 2/3 Terminated
NCT00698204 2014-06-05
Cox-2 Inhibition in Radiation-induced Oral Mucositis
UConn Health
Phase 2 Completed
NCT00061906 2014-02-11
Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00589186 2013-12-18
Vaccine Therapy and Celecoxib in Treating Patients With Metastatic Nasopharyngeal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00101335 2013-07-11
Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia
Fox Chase Cancer Center
Phase 2 Completed
NCT00581971 2013-04-25
RAD0201
University of Alabama at Birmingham
Phase 1/2 Completed
NCT00014404 2013-01-16
Celecoxib in Treating Patients With Precancerous Lesions of the Mouth
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00527982 2012-12-06
Celecoxib as Adjuvant Biologic Therapy in Patients With Head and Neck and Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00592319 2012-08-31
Celebrex (Celecoxib) Treatment of Laryngeal Papilloma
Boston University
Phase 2 Terminated
NCT00058006 2012-06-11
Celecoxib in Treating Patients With Early-Stage Head and Neck Cancer or Non-Small Cell Lung Cancer
Northwestern University
Phase 2 Completed
NCT00212108 2012-04-02
A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839
National University Hospital, Singapore
Phase 1/2 Completed
NCT00357617 2010-12-24
Celecoxib in Treating Patients With Head and Neck Cancer That Can Be Removed By Surgery
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00603759 2008-01-29
COX-2 Inhibitor With Concurrent Chemoradiation in Locally Advanced Head & Neck Carcinoma
Tehran University of Medical Sciences
Phase 3 Unknown